Changes in Hong Kong stocks | Quanxin Biotech B (02509) rose more than 5%, and the three long-term dual antibodies went overseas successfully. Institutions are optimistic about the company's leading position in the field of self-protection

The Zhitong Finance App learned that Quanxin Biotech B (02509) rose by more than 5%. As of press release, it had risen 5% to HK$18.9, with a turnover of HK$13.509 million.

According to the news, on December 22, Quanxin Biotech announced that it had reached an authorization with Windward's subsidiary for a total amount of up to US$700 million for the TSLPxIL-13 dual antibody drug. It is worth mentioning that this is the third overseas deal that Quanxin Biotech has reached this year. Previously, the company granted the QX030N global rights to Caldera and authorized the QX031N to Roche.

China Post Securities pointed out that the company is a leader in innovative self-defense drugs in China and has a good track record in the field of self-defense innovative drugs. The company's mature pipelines are gradually entering the fulfillment period to improve hematopoietic capacity, and authorizations for innovative pipelines to go overseas have been granted one after another, providing a further guarantee for the company's steady operation. Huachuang Securities said it is optimistic that the company will continue to consolidate its leading position in the field of self-defense.